Edgar Filing: DEXCOM INC - Form 4

Check this box if no longer subject to SEction 16. Number: Number: Number: Vashington, D.C. 20549 Number: Sanuary 31 2005 Estimated average burden hours per									3235-0287 January 31, 2005 Iverage		
1. Name and A Balo Andrey	address of Reporting F w K	2. Issuer Name and Ticker or Trading Symbol DEXCOM INC [DXCM]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(N			3. Date of Earliest Transaction(Month/Day/Year)05/02/2006				Director 10% Owner Officer (give title Other (specify below) below) VP of Clinical & Regulatory				
				Amendment, Date Original Month/Day/Year)				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip) T	able I - Non-I	Derivative Se	curiti	es Acq	uired, Disposed of	, or Beneficial	ly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		ned 3. 4. Securities Acquin n Date, if Transaction(A) or Disposed of Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8) (A) or			of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
Common Stock	05/02/2006		Code V M	⁷ Amount 11,500	(D) A	Price \$ 0.3	64,876 <u>(1)</u>	D			
Common Stock	05/02/2006		М	36,000	A	\$ 0.5	100,876	D			
Common Stock	05/02/2006		S	100,000 (2)	D	\$ 24	876	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

Edgar Filing: DEXCOM INC - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (Right to Buy)	\$ 0.3	05/02/2006		М	11,500	(3)	02/19/2012	Common Stock	11,500
Incentive Stock Option (Right to Buy)	\$ 0.5	05/02/2006		М	36,000	<u>(3)</u>	01/29/2013	Common Stock	36,000

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
Balo Andrew K C/O DEXCOM, INC. 5555 OBERLIN DRIVE SAN DIEGO, CA 92121			VP of Clinical & Regulatory				
Clanaturaa							

Signatures

/s/ Andrew K. Balo <u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 876 shares acquired on January 31, 2006 under DexCom's Employee Stock Purchase Plan.
- (2) Shares sold in connection with follow-on public offering pursuant to S-1 Registration Statement.

(3) Not applicable.

Remarks:

This Statement confirms that the undersigned, Andrew K. Balo, has authorized and designated Nooshin Hussainy and Jess Roj

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.